Ulys, L.L.C.
- SEC CIK
- 0001340098
- Latest filing
- May 14, 2021
The latest 13F from Ulys, L.L.C. covers Q1 2021 (filed May 14, 2021): 1 long positions worth $25.4M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Lexicon Pharmaceuticals, Inc. (LXRX) at 100.0%. Livermore has 1 filing on Form 13F from this institution, going back to Q1 2021.
What changed in Q1 2021
The five largest holdings this quarter.
Livermore's 13F data starts with Q1 2021, so there is no earlier quarter to compare with.
Metrics
13F metrics for Q1 2021, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $25.4M
- No prior quarter to compare
- Positions
- 1
- No prior quarter to compare
- Top 10 concentration
- 100.0%
- Top 10 as share of value
- Turnover
- –
- No prior quarter to compare
- Average holding period
- 1.0 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
Only Q1 2021 so far.
13D and 13G filings
Companies where Ulys, L.L.C. reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
Ulys, L.L.C. does not currently report owning 5% or more of any company.
Latest filings
20 filings on file made by Ulys, L.L.C. or listing it as a reporting person, newest first.
| Company | Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|---|
| OLMAOlema Pharmaceuticals, Inc. | Mar 20, 202610:37 AM ET | Invus Global Management, LLCand 7 others | 13G | 5.10%4.46M shares | New | Mar 16, 2026 | SEC |
| BCYCBicycle Therapeutics PLC | Mar 3, 20265:39 PM ET | Invus Global Management, LLCand 7 others | 13G | 6.30%3.15M shares | New | Feb 25, 2026 | SEC |
| NMRANeumora Therapeutics, Inc. | Feb 19, 20264:37 PM ET | Invus Global Management, LLCand 7 others | 13G | 5.40%9.00M shares | New | Feb 13, 2026 | SEC |
| TNGXTango Therapeutics, Inc. | Feb 13, 202611:47 AM ET | Invus Global Management, LLCand 7 others | 13G/A | 6.10%8.17M shares | +0.80 ppfrom 5.30% | Dec 31, 2025 | SEC |
| RZLTRezolute, Inc. | Feb 13, 202611:40 AM ET | Invus Global Management, LLCand 7 others | 13G/A | 0.00%0 shares | −5.40 ppfrom 5.40%Below 5% | Dec 31, 2025 | SEC |
| DBVTDBV Technologies S.A. | Feb 13, 202611:25 AM ET | Invus Global Management, LLCand 7 others | 13G/A | 6.20%14.4M shares | −1.60 ppfrom 7.80% | Dec 31, 2025 | SEC |
| ENGNenGene Therapeutics Inc. | Jan 27, 20262:18 PM ET | Invus Global Management, LLCand 7 others | 13G | 6.30%4.24M shares | New | Jan 21, 2026 | SEC |
| VTVTvTv Therapeutics Inc. | Nov 12, 202510:29 AM ET | Invus Global Management, LLCand 7 others | 13G/A | 9.40%393.1K shares | −0.59 ppfrom 9.99% | Sep 30, 2025 | SEC |
| RANIRani Therapeutics Holdings, Inc. | Oct 23, 20255:05 PM ET | Invus Global Management, LLCand 7 others | 13G | 9.99%9.83M shares | New | Oct 16, 2025 | SEC |
| DBVTDBV Technologies S.A. | Oct 14, 20255:14 PM ET | Invus Global Management, LLCand 7 others | 13G | 7.80%11.5M shares | New | Oct 6, 2025 | SEC |
| TENXTenax Therapeutics, Inc. | Oct 2, 20255:04 PM ET | Invus Global Management, LLCand 7 others | 13G | 9.40%427.1K shares | New | Sep 26, 2025 | SEC |
| TNGXTango Therapeutics, Inc. | Sep 22, 20255:22 PM ET | Invus Global Management, LLCand 7 others | 13G | 5.30%5.88M shares | New | Sep 19, 2025 | SEC |
| RZLTRezolute, Inc. | Sep 22, 20253:15 PM ET | Invus Global Management, LLCand 7 others | 13G | 5.40%4.87M shares | New | Sep 18, 2025 | SEC |
| VTVTvTv Therapeutics Inc. | Sep 8, 20255:43 PM ET | Invus Global Management, LLCand 7 others | 13G | 9.99%348.1K shares | New | Aug 29, 2025 | SEC |
| BCAXBicara Therapeutics Inc. | Jul 31, 20252:56 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 9.60%5.22M shares | – | Jun 30, 2025 | SEC |
| SLDBSolid Biosciences Inc. | Apr 17, 20256:50 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 9.60%7.42M shares | +0.20 ppfrom 9.40% | Mar 31, 2025 | SEC |
| SLDBSolid Biosciences Inc. | Feb 12, 20254:30 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 9.40%3.75M shares | – | Dec 31, 2024 | SEC |
| VIGLVigil Neuroscience, Inc. | Feb 12, 20254:30 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 4.90%1.99M shares | –Below 5% | Dec 31, 2024 | SEC |
| GOSSGossamer Bio, Inc. | Feb 12, 20254:30 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 2.80%6.26M shares | –Below 5% | Dec 31, 2024 | SEC |
| SYRSSyros Pharmaceuticals, Inc. | Feb 12, 20254:30 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 3.80%1.06M shares | –Below 5% | Dec 31, 2024 | SEC |